Handa et al. also verified that NSCLC patients (Stage I) with high levels of PD-L1 (>5%) had a worse prognosis than patients with low levels of PD-L1 (five-year RFS: high 63.4% vs. low 81%, p = 0.061). The gene discussed is CD274; the disease is non-small cell lung carcinoma.